Preparation, characterization, cellular uptake and evaluation in vivo of solid lipid nanoparticles loaded with cucurbitacin B

References

• Chen JC, Chiu MH, Nie RL, Cordell GA, Qiu SX. (2005). Cucurbitacins and cucurbitane glycosides: structures and biological activities. Nat Prod Rep, 22:386–399.
   PubMed Web of Science ®Google Scholar
• Peters RR, Saleh TF, Lora M, Patry C, de Brum-Fernandes AJ, Farias MR et al. (1999). Anti-inflammatory effects of the products from Wilbrandia ebracteata on carrageenan-induced pleurisy in mice. Life Sci, 64:2429–2437.
   PubMed Web of Science ®Google Scholar
• Yesilada E, Tanaka S, Sezik E, Tabata M. (1988). Isolation of an anti-inflammatory principle from the fruit juice of Ecballium elaterium. J Nat Prod, 51:504–508.
   PubMed Web of Science ®Google Scholar
• Agil A, Miró M, Jimenez J, Aneiros J, Caracuel MD, García-Granados A et al. (1999). Isolation of ani-hepatotoxic principle form the juice of Ecballium elaterium. Planta Med, 65:673–675.
   PubMed Web of Science ®Google Scholar
• Oh H, Mun YJ, Im SJ, Lee SY, Song HJ, Lee HS et al. (2002). Cucurbitacins from Trichosanthes kirilowii as the inhibitory components on tyrosinase activity and melanin synthesis of B16/F10 melanoma cells. Planta Med, 68:832–833.
   PubMed Web of Science ®Google Scholar
• Ukiya M, Akihisa T, Yasukawa K, Tokuda H, Toriumi M, Koike K et al. (2002). Anti-inflammatory and anti-tumor-promoting effects of cucurbitane glycosides from the roots of Bryonia dioica. J Nat Prod, 65:179–183.
   PubMed Web of Science ®Google Scholar
• Tannin-Spitz T, Grossman S, Dovrat S, Gottlieb HE, Bergman M. (2007). Growth inhibitory activity of cucurbitacin glucosides isolated from Citrullus colocynthis on human breast cancer cells. Biochem Pharmacol, 73:56–67.
   PubMed Web of Science ®Google Scholar
• Bartalis J, Halaweish FT. (2005). Relationship between cucurbitacins reversed-phase high-performance liquid chromatography hydrophobicity index and basal cytotoxicity on HepG2 cells. J Chromatogr B Analyt Technol Biomed Life Sci, 818:159–166.
   PubMed Web of Science ®Google Scholar
• Marengo E, Cavalli R, Caputo O, Rodriguez L, Gasco MR. (2000). Scale-up of the preparation process of solid lipid nanospheres. Part I. Int J Pharm, 205:3–13.
   PubMed Web of Science ®Google Scholar
• Müller RH, Mäder K, Gohla S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm, 50:161–177.
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Hunter AC, Murray JC. (2001). Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev, 53:283–318.
   PubMed Web of Science ®Google Scholar
• Maeda H. (2001). SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv Drug Deliv Rev, 46:169–185.
   PubMed Web of Science ®Google Scholar
• Muggia FM. (1999). Doxorubicin-polymer conjugates: further demonstration of the concept of enhanced permeability and retention. Clin Cancer Res, 5:7–8.
   PubMed Web of Science ®Google Scholar
• Maeda H, Matsumura Y. (1989). Tumoritropic and lymphotropic principles of macromolecular drugs. Crit Rev Ther Drug Carrier Syst, 6:193–210.
   PubMed Web of Science ®Google Scholar
• Bhardwaj V, Ankola DD, Gupta SC, Schneider M, Lehr CM, Kumar MN. (2009). PLGA nanoparticles stabilized with cationic surfactant: safety studies and application in oral delivery of paclitaxel to treat chemical-induced breast cancer in rat. Pharm Res, 26:2495–2503.
   PubMed Web of Science ®Google Scholar
• Wang JX, Sun X, Zhang ZR. (2002). Enhanced brain targeting by synthesis of 3′,5′-dioctanoyl-5-fluoro-2′-deoxyuridine and incorporation into solid lipid nanoparticles. Eur J Pharm Biopharm, 54:285–290.
   PubMed Web of Science ®Google Scholar
• Weyenberg W, Filev P, Van den Plas D, Vandervoort J, De Smet K, Sollie P et al. (2007). Cytotoxicity of submicron emulsions and solid lipid nanoparticles for dermal application. Int J Pharm, 337:291–298.
   PubMed Web of Science ®Google Scholar
• Labouret A, Thioune O, Fessi H, Devissaguet JP, Puisieux F. (1995). Application of an original process for obtaining colloidal dispersions of some coats polymers. Preparation, characterization, industrial scaling up. Drug Dev Ind Pharm, 21:229–241.
   Web of Science ®Google Scholar
• Torchilin VP. (2010). Passive and active drug targeting: drug delivery to tumors as an example. Handb Exp Pharmacol, 197:3–53.
   PubMedGoogle Scholar
• Nomura T, Koreeda N, Yamashita F, Takakura Y, Hashida M. (1998). Effect of particle size and charge on the disposition of lipid carriers after intratumoral injection into tissue-isolated tumors. Pharm Res, 15:128–132.
   PubMed Web of Science ®Google Scholar
• Schwarz C, Mehnert W, Lucks JS, Müller RH (1994). Solid lipid nanoparticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization. J Control Release, 30:83–96.
   Web of Science ®Google Scholar
• Kedmi R, Ben-Arie N, Peer D. (2010). The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. Biomaterials, 31:6867–6875.
   PubMed Web of Science ®Google Scholar
• Lockman PR, Koziara JM, Mumper RJ, Allen DD. (2004). Nanoparticle surface charges alter blood-brain barrier integrity and permeability. J Drug Target, 12:635–641.
   PubMed Web of Science ®Google Scholar
• Schäfer-Korting M, Mehnert W, Korting HC. (2007). Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv Drug Deliv Rev, 59:427–443.
   PubMed Web of Science ®Google Scholar
• Bartalis J, Halaweish FT. (2011). In vitro and QSAR studies of cucurbitacins on HepG2 and HSC-T6 liver cell lines. Bioorg Med Chem, 19:2757–2766.
   PubMed Web of Science ®Google Scholar
• Lee MK, Choi L, Kim MH, Kim CK. (1999). Pharmacokinetics and organ distribution of cyclosporin A incorporated in liposomes and mixed micelles. Int J Pharm, 191:87–93.
   PubMed Web of Science ®Google Scholar
• Park KM, Lee MK, Hwang KJ, Kim CK. (1999). Phospholipid-based microemulsions of flurbiprofen by the spontaneous emulsification process. Int J Pharm, 183:145–154.
   PubMed Web of Science ®Google Scholar
• Hurrell S, Cameron RE. (2003). The effect of buffer concentration, pH and buffer ions on the degradation and drug release from polyglycolide. Polym Int, 52:358–366.
   Web of Science ®Google Scholar
• Liu J, Zhu J, Du Z, Qin B. (2005). Preparation and pharmacokinetic evaluation of Tashinone IIA solid lipid nanoparticles. Drug Dev Ind Pharm, 31:551–556.
   PubMed Web of Science ®Google Scholar
• Wissing SA, Kayser O, Müller RH. (2004). Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev, 56:1257–1272.
   PubMed Web of Science ®Google Scholar
• Meng W, Parker TL, Kallinteri P, Walker DA, Higgins S, Hutcheon GA et al. (2006). Uptake and metabolism of novel biodegradable poly (glycerol-adipate) nanoparticles in DAOY monolayer. J Control Release, 116:314–321.
   PubMed Web of Science ®Google Scholar
• Jensen KD, Nori A, Tijerina M, Kopecková P, Kopecek J. (2003). Cytoplasmic delivery and nuclear targeting of synthetic macromolecules. J Control Release, 87:89–105.
   PubMed Web of Science ®Google Scholar
• Panyam J, Labhasetwar V. (2003). Dynamics of endocytosis and exocytosis of poly(D,L-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells. Pharm Res, 20:212–220.
   PubMed Web of Science ®Google Scholar
• Chavanpatil MD, Khdair A, Panyam J. (2006). Nanoparticles for cellular drug delivery: mechanisms and factors influencing delivery. J Nanosci Nanotechnol, 6:2651–2663.
   PubMed Web of Science ®Google Scholar
• Park K, Kim JH, Nam YS, Lee S, Nam HY, Kim K et al. (2007). Effect of polymer molecular weight on the tumor targeting characteristics of self-assembled glycol chitosan nanoparticles. J Control Release, 122:305–314.
   PubMed Web of Science ®Google Scholar
• Hu Y, Xie J, Tong YW, Wang CH. (2007). Effect of PEG conformation and particle size on the cellular uptake efficiency of nanoparticles with the HepG2 cells. J Control Release, 118:7–17.
   PubMed Web of Science ®Google Scholar
• Sahoo SK, Panyam J, Prabha S, Labhasetwar V. (2002). Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release, 82:105–114.
   PubMed Web of Science ®Google Scholar
• Tranchant T, Besson P, Hoinard C, Delarue J, Antoine JM, Couet C et al. (1997). Mechanisms and kinetics of alpha-linolenic acid uptake in Caco-2 clone TC7. Biochim Biophys Acta, 1345:151–161.
   PubMed Web of Science ®Google Scholar
• Yuan H, Miao J, Du YZ, You J, Hu FQ, Zeng S. (2008). Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells. Int J Pharm, 348:137–145.
   PubMed Web of Science ®Google Scholar
• Nassimi M, Schleh C, Lauenstein HD, Hussein R, Hoymann HG, Koch W et al. (2010). A toxicological evaluation of inhaled solid lipid nanoparticles used as a potential drug delivery system for the lung. Eur J Pharm Biopharm, 75:107–116.
   PubMed Web of Science ®Google Scholar
• Silva AC, González-Mira E, García ML, Egea MA, Fonseca J, Silva R et al. (2011). Preparation, characterization and biocompatibility studies on risperidone-loaded solid lipid nanoparticles (SLN): high pressure homogenization versus ultrasound. Colloids Surf B Biointerfaces, 86:158–165.
   PubMed Web of Science ®Google Scholar
• Manjunath K, Venkateswarlu V. (2005). Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Release, 107:215–228.
   PubMed Web of Science ®Google Scholar
• Jiang W, Kim BY, Rutka JT, Chan WC (2008). Nanoparticle-mediated cellular response is size-dependent. Nat Nanotechnol, 3:145–150.
   PubMed Web of Science ®Google Scholar
• Stolnik S, Illum L, Davis SS.(1995). Long circulating microparticulate drug carriers. Adv Drug Deliv Rev, 16:195–214.
   Web of Science ®Google Scholar
• Danhier F, Vroman B, Lecouturier N, Crokart N, Pourcelle V, Freichels H et al. (2009). Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel. J Control Release, 140:166–173.
   PubMed Web of Science ®Google Scholar
• Vicent MJ, Duncan R. (2006). Polymer conjugates: nanosized medicines for treating cancer. Trends Biotechnol, 24:39–47.
   PubMed Web of Science ®Google Scholar
• Maeda H. (2001). The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul, 41:189–207.
   PubMedGoogle Scholar
• Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. (2000). Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release, 65:271–284.
   PubMed Web of Science ®Google Scholar
• Gaumet M, Vargas A, Gurny R, Delie F. (2008). Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. Eur J Pharm Biopharm, 69:1–9.
   PubMed Web of Science ®Google Scholar
• Olivier JC, Huertas R, Lee HJ, Calon F, Pardridge WM. (2002). Synthesis of pegylated immunonanoparticles. Pharm Res, 19:1137–1143.
   PubMed Web of Science ®Google Scholar
• Yang SC, Lu LF, Cai Y, Zhu JB, Liang BW, Yang CZ. (1999). Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Release, 59:299–307.
   PubMed Web of Science ®Google Scholar